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The aim of this study was to clarify the genetic backgrounds
underlyingthe clinicopathological characteristicsof urothelialcar-
cinomas(UCs). Arraycomparative genomic hybridizationanalysis
using a 244K oligonucleotide array was performed on 49 samples
of UC tissue. Losses of 2q33.3–q37.3, 4p15.2–q13.1 and 5q13.3–
q35.3 and gains of 7p11.2–q11.23 and 20q13.12–q13.2 were corre-
latedwith higher histologicalgrade, and gainof7p21.2–p21.12 was
correlated with deeper invasion. Losses of 6q14.1–q27 and
17p13.3–q11.1 and gains of 19q13.12–q13.2 and 20q13.12–q13.33
were correlated with lymph vessel involvement. Loss of 16p12.2–
p12.1 and gain of 3q26.32–q29 were correlated with vascular in-
volvement. Losses of 5q14.1–q23.1, 6q14.1–q27, 8p22–p21.3,
11q13.5–q14.1 and 15q11.2–q22.2 and gains of 7p11.2–q11.22
and 19q13.12–q13.2 were correlated with the development of ag-
gressive non-papillary UCs. Losses of 1p32.2–p31.3, 10q11.23–
q21.1 and 15q21.3 were correlated with tumor recurrence. Unsu-
pervised hierarchical clustering analysis based on copy number
alterations clustered UCs into threesubclasses: copy number alter-
ations associated with genome-wide DNA hypomethylation, re-
gional DNA hypermethylation on C-type CpG islands and
genome-wide DNA hypo- and hypermethylationwere accumulated
in clusters A, B1 and B2, respectively. Tumor-related genes that
may encode therapeutic targets and/or indicators useful for the
diagnosis and prognostication of UCs should be explored in the
above regions. Both genetic and epigenetic events appear to accu-
mulate during urothelial carcinogenesis, reﬂecting the clinicopath-
ological diversity of UCs.
Introduction
Urothelial carcinomas (UCs) are classiﬁed as superﬁcial papillary car-
cinomas or non-papillary carcinomas according to their conﬁguration
(1). Papillary carcinomas usually remain non-invasive although pa-
tients need to undergo repeated urethrocystoscopic resection for
recurrences. In contrast, non-papillary invasive carcinomas usually
develop from widely spreading ﬂat carcinomas in situ showing
a higher histological grade, and their clinical outcome is poor. There
is also an alternative pathway by which papillary carcinomas de-
velop higher histological grades during repetitive recurrence and
transform into non-papillary invasive carcinomas. Thus, UCs show
marked clinicopathological diversity (2). In order to improve the
efﬁciency of diagnosis and therapy, it is necessary to clarify the
genetic backgrounds underlying the various clinicopathological
characteristics of UCs.
Previous studies employing Southern blotting based on restriction
enzyme length polymorphism, polymerase chain reaction (PCR)–
loss of heterozygosity (LOH) analysis using microsatellite markers,
comparative genomic hybridization (CGH) analysis and ﬂuores-
cence in situ hybridization (FISH) have revealed chromosomal in-
stability in UCs such as losses of 2q, 5q, 9q and 10q and gains of 5p,
7p, 8q, 11q and 20q (3–12). However, such approaches are not
effective for deﬁning the break points in detail. Although recently
developed array-based technology has been applied to UCs (13–18),
the resolution of the arrays employed was insufﬁcient or correlations
between copy number alterations and the clinicopathological param-
eters of UCs were not analyzed in detail. Therefore, the genetic
backgrounds underlying urothelial carcinogenesis have not been
fully clariﬁed.
In addition, multistage carcinogenesis is known to comprise
both genetic and epigenetic events (19–21). We have reported the
accumulation of DNA methylation on C-type CpG islands (22) in
a cancer-speciﬁc, but not age-dependent, manner and demonstrated
protein overexpression of DNA methyltransferase 1, a major DNA
methyltransferase, even in non-cancerous urothelia with no apparent
histological changes obtained from patients with UCs (23,24), as
a result of possible exposure to carcinogens in the urine at the pre-
cancerous stage. Accumulation of DNA methylation on C-type CpG
islands associated with DNA methyltransferase 1 protein overex-
pression was more frequently evident in aggressive non-papillary
UCs (23,24). DNA hypomethylation on pericentromeric satellite
regions was signiﬁcantly correlated with LOH on chromosome 9
in UCs (25). Moreover, we have identiﬁed optimal indicators for
carcinogenetic risk estimation in histologically normal urothelia,
and for prognostication in surgically resected specimens from
patients with UCs (26) using the bacterial artiﬁcial chromosome
array-based methylated CpG island ampliﬁcation (BAMCA)
method (27–29), which is suitable for overviewing the DNA meth-
ylation tendency ofindividual large regions among all chromosomes
(30). Although these data indicated that not only genetic but also
epigenetic alterations play signiﬁcant roles in UC development, to
our knowledge, the correlations between copy number alterations
and DNA methylation proﬁles in UCs have not been examined in
a genome-wide manner.
Inthepresentstudy of49UCs,weanalyzedcopy numberalterations
by array CGH analysis using a high-resolution (244K) oligonucleotide
array, DNA methylation alterations on a genome-wide scale using
BAMCA and DNA methylation status on C-type CpG islands using
bisulﬁte modiﬁcation. We then examined the clinicopathological sig-
niﬁcance of copy number alterations and the correlations between
alterations of copy number and those of DNA methylation.
Abbreviations: BAC, bacterial artiﬁcial chromosome; BAMCA, bacterial ar-
tiﬁcial chromosome array-based methylated CpG island ampliﬁcation; CGH,
comparative genomic hybridization; COBRA, combined bisulﬁte restriction
enzyme analysis; FISH, ﬂuorescence in situ hybridization; LOH, loss of het-
erozygosity; mRNA, messenger RNA; MINT, methylated in tumor; MSP,
methylation-speciﬁc polymerase chain reaction; RT, reverse transcription;
PCR, polymerase chain reaction; UC, urothelial carcinoma.
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Patients and tissue samples
Forty-nine samples (T1 to T49) of UCs of the urinary bladder, ureter and renal
pelvis were obtained from specimens that had been surgically resected by
radical cystectomy (16 patients) or nephroureterectomy (33 patients) at the
National Cancer Center Hospital, Tokyo, Japan. The patients comprised 38
men and 11 women whose mean age was 68.59 ± 10.11 (mean ± standard
deviation) years (range 49–85 years). Among the UCs, 19 and 30 were graded
as low- and high-grade tumors, respectively, on the basis of the World Health
Organization classiﬁcation (31), and 34 and 15 were classed as superﬁcial
(pTis, pTa, pT1) and invasive (pT2 or more), respectively (31). Histological
examination of UCs revealed lymph vessel involvement in 16 and vascular
involvement in 9. On the basis of macroscopic examination, the UCs were
divided into 28 papillary tumors and 21 non-papillary tumors. Five patients
were positive for lymph node metastasis at the point of radical cystectomy or
nephroureterectomy. Recurrence was diagnosed by urologists mainly on the
basis of computed tomography, abdominal ultrasonography and urine cytolog-
ical examinations. The mean observation period was 39.7 ± 31.8 months
(mean ± standard deviation) and seven patients were positive for recurrence
(lymph node metastasis, local recurrence and metastasis to the lung or bone in
three, two and two patients, respectively). Clinicopathological parameters for
each of the examined patients are summarized in supplementary Table S1,
available at Carcinogenesis Online. This study was approved by the Ethics
Committee of the National Cancer Center, Tokyo, Japan and was performed in
accordance with the Declaration of Helsinki 1995. All patients gave their in-
formed consent prior to their inclusion in this study.
Array CGH analysis
High-molecular-weight DNA from fresh-frozen tissue samples was extracted
using phenol–chloroform, followed by dialysis. ArrayCGHwasperformed using
a Human Genome CGH 244K Oligo Microarray Kit (Agilent Technologies,
Santa Clara, CA). Labeling and hybridization were performed according to the
manufacturer’s protocol (Protocol v4.0, June 2006). Brieﬂy, 2 lgo fD N Af r o m
the patient and from a sex-matched control were double digested with AluI
and RsaI (Promega, Madison, WI) for 2 h at 37C. The digested DNAwas then
labeled by random priming using an Agilent Genomic DNA Labeling Kit Plus.
Patient DNA and control DNA were labeled with Cy5-dUTP and Cy3-dUTP,
respectively, and the labeled DNAs were hybridized with human Cot I DNA at
65C with rotation for 40 h. Arrays were analyzed using the Agilent DNA micro-
array scanner and the Agilent Feature Extraction software. Presentation of the
results was obtained using the Agilent CGH Analytics software package.
The results of array CGH were validated by FISH analysis. An LSI p16
(9p21) SpectrumOrange/CEP 9 SpectrumGreen Probe and an LSI p53
(17p13.1) SpectrumOrange Probe (Abbott/Vysis, Abbott Park, IL), corre-
sponding to the CDKN2A and TP53 loci, respectively, were used. The FISH
probes were hybridized to 5 lm thick sections of formalin-ﬁxed, parafﬁn-
embedded tissue specimens taken from a region immediately adjacent to that
from which the corresponding fresh-frozen sample had been obtained within
the same UC. Nuclei were stained with 4,5-diamidino-2-phenylindole.
BAC array-based methylated CpG island ampliﬁcation
Because DNA methylation status is known to be organ speciﬁc (32), the
reference DNA for analysis of the developmental stages of UCs should be
obtained from the urothelium and not from other tissues or peripheral blood.
Therefore, a mixture of normal urothelial DNA obtained from 11 male patients
(C19 to C29) and 6 female patients (C30 to C35) without UCs was used as
a reference for analyses of male and female test DNA samples, respectively. Of
these 17 patients, 13 and 4 had undergone nephrectomy for renal cell carci-
noma and nephrectomy for retroperitoneal sarcoma around the kidney, respec-
tively. The mean age of the patients from whom normal urothelia had been
obtained was 66.18 ± 10.49 (mean ± standard deviation) years (range 54–82
years). DNA methylation status was analyzed by BAMCA using a custom-
made array (molecular cytogenetics Whole Genome Array-4500) harboring
4361 bacterial artiﬁcial chromosome (BAC) clones located throughout chro-
mosomes 1–22, X and Y (33), as described previously (34,35). In 40 samples
of UCs (T1 to T40), BAMCA had been performed and the results have already
been published (26). For the present study, BAMCA was performed on nine
additional samples of UCs (T41 to T49), and correlations between DNA meth-
ylation status and copy number alterations were examined in all 49 UCs.
Methylation-speciﬁc PCR and combined bisulﬁte restriction enzyme analysis
DNA methylation status on 5 C-type CpG islands was analyzed by methylation-
speciﬁc polymerase chain reaction (MSP) and combined bisulﬁte restriction
enzyme analysis (COBRA), as described previously (36). Brieﬂy, bisulﬁte
conversion was carried out using a CpGenome DNA Modiﬁcation Kit (Chem-
icon International, Temecula, CA). DNA methylation status on CpG islands of
the p16 and hMLH1 genes was determined by MSP using the primers de-
scribed previously (36). The DNA methylation status of the methylated in
tumor (MINT)-1, MINT-2 and MINT-12 clones was determined by COBRA
using previouslydescribed primersand restriction enzymes (36). In 40 samples
of UCs (T1 to T40), MSP and COBRA had been performed and the results
have already been published (26). For the present study, MSP and COBRA
were performed on nine additional samples of UCs (T41 to T49), and corre-
lations between DNA methylation status and copy number alterations were
examined in all 49 UCs.
Statistics
Correlations between copy number alterations and clinicopathological param-
eters of UCs were analyzed using the unpaired T-test. Based on Bonferroni
correction for multiplicity of testing, differences at P , 0.00714 were consid-
ered signiﬁcant. Unsupervised two-dimensional hierarchical clustering analy-
sis of UCs was done using GeneSpring GX 10.0. Differences in the average
number of array CGH probes showing copy number alterations, the average
number of BAC clones showing DNA methylation alterations (hypo- and
hypermethylation) and the average number of C-type CpG islands showing
DNA methylation in UCs belonging to clusters A, B1 and B2 yielded by the
unsupervised hierarchical clustering were analyzed using the Kruskal–Wallis
test. Differences at P , 0.05 were considered signiﬁcant.
Fig. 1. Validation of array CGH analysis by FISH. (A) Array CGH proﬁles of
representative tissue specimens (T1 to T4). The signal ratios of the CDKN2
locus in T1, T2 and T3 corresponded to copy numbers of 0, 1 and 2,
respectively, whereas the signal ratio in T4 did not correspond to any whole
number. (B) Although the LSI p16 (9p21) SpectrumOrange/CEP 9
SpectrumGreen Probe corresponding to the CDKN2A gene revealed two
signals in stromal cells and adjacent non-cancerous urothelial cells, it revealed
no signal in cancer cells in T1. (C) FISH analysis using the same probe
revealed one signal in cancer cells in T2. (D) FISH analysis using the same
probe revealed two signals in cancer cells in T3. (E) FISH analysis using the
same probe revealed copy number heterogeneity in T4: cancer cells in areas 1
and 2 showed two signals and one signal within a tumor, respectively. These
ﬁndings can explain the array CGH proﬁle of T4 in panel (A).
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Validation of array CGH analysis by FISH
The array CGH analysis for copy number alterations was validated
by FISH. Examples of array CGH proﬁles and FISH images of
the four representative UCs (T1 to T4) are shown in Figure 1A–E,
respectively. The signal ratios of the CDKN2A locus in T1, T2 and T3
corresponded to copy numbers of 0, 1 and 2, respectively, whereas the
signal ratio in T4 did not correspond to any whole numbers (Figure
1A). The LSI p16 (9p21) SpectrumOrange/CEP 9 SpectrumGreen
Probe corresponding to the CDKN2A gene revealed two signals in
stromal cells and adjacent non-cancerous urothelial cells on the spec-
imen of T1 (Figure 1B). The probe revealed zero, one and two signals
in cancer cells in T1, T2 and T3, respectively (Figure 1B–D). FISH
analysis revealed copy number heterogeneity within a UC: cancer
cells showing two signals and those showing one signal were both
observed in T4 (Figure 1E). These ﬁndings were able to explain the
array CGH proﬁle in T4 (Figure 1A). Similarly FISH analysis using
the LSI p53 (17p13.1) SpectrumOrange Probe corresponding to the
TP53 gene also validated the array CGH proﬁles (data not shown).
Copy number alterations and their clinicopathological impact in UCs
Figure 2 shows an overview of the copy number alterations on chro-
mosomes 1–22 in all examined UCs. Chromosomal regions in which
the incidence of copy number alterations in all examined UCs were
 20% are summarized in Table I. If a UC showed copy number het-
erogeneity like that of T4 in Figure 1, the copy number observed in the
major area within the tumor was described as the copy number of the
UC in Figure 2 and Table I. On 3q26.1 and 4q13.2 (arrows inFigure 2),
the incidence of homozygous deletion (copy number 0) on only 10 and
11 continuous oligonucleotide probes was high (59.2 and 67.3%, re-
spectively, Table I). Although copy number polymorphism has been
reportedintheaboveregion on 3q26.1,theUGT2B17gene,whichmay
be associated with smoking-related cancers (37), is the only gene re-
portedtobelocatedwithinthehomozygouslydeletedregionon4q13.2.
Chromosomal loci on which copy number alterations were signiﬁ-
cantlycorrelatedwithclinicopathologicalparametersofUCsareshown
in Figure 2. The clinicopathological impacts of the copy number alter-
ations are also summarized in Figure 3. For example, loss of 1p32.2–
p31.3 was correlated with UC recurrence. Loss of 2q33.3–q37.3 was
correlated with higher histological grade. Gain of 3q26.32–q29 was
correlated with vascular involvement. Loss of 4p15.2–q13.1 was cor-
related with higher histological grade. Losses of 5q13.3–q35.3 and
5q14.1–q23.1 were correlated with higher histological grade and tumor
conﬁguration (development of non-papillary tumors), respectively.
Lossof6q14.1–q27wascorrelatedwithbothlymphvesselinvolvement
and tumor conﬁguration. Gains of 7p21.2–p21.12, 7p11.2–q11.22
and 7p11.2–q11.23 were correlated with deeper invasion, tumor
Fig. 2. Copy number alterations and their clinicopathological impacts in UCs. The incidence of copy number alterations on chromosomes 1–22 in UCs (T1 to
T49) is shown. Gains (copy number:  3) and losses (copy number: 1 or 0) are shown in the upper and lower halves, respectively. Copy numbers of 0, 1, 3 and more
are shown in dark red, light red, light blue and dark blue, respectively. The homozygously deleted regions on 3q26.1 and 4q13.2 are indicated by arrows. Locations
of the array CGH probe on which copy number alterations were signiﬁcantly correlated (unpaired T-test with Bonferroni correction, P , 0.00714) with
histological grade (a), depth of invasion (b), lymph vessel involvement (c), vascular involvement (d), tumor conﬁguration (papillary versus non-papillary,
(e) lymph node metastasis (f) and recurrence (g) of UCs are indicated by ‘X’ under each of the histograms for chromosomes 1–22.
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p21.3wascorrelatedwithtumorconﬁguration.Lossof10q11.23–q21.1
was correlated with UC recurrence. Loss of 11q13.5–q14.1 was corre-
lated with tumor conﬁguration. Losses of 15q11.2–q22.2 and 15q21.3
were correlated with tumor conﬁguration and recurrence, respectively.
Loss of 16p12.2–p12.1 was correlated with vascular involvement of
UCs. Loss of 17p13.3–q11.1 was correlated with lymph vessel involve-
ment. Gain of 19q13.12–q13.2 was correlated with lymph vessel in-
volvement and tumor conﬁguration. Gains of 20q13.12–q13.2 and
20q13.12–q13.33 were correlated with higher histological grade and
lymph vessel involvement, respectively. On the other hand, although
the incidences of 8q gain and 9p, 11p and 14q loss were generally high
in UCs, such copy number alterations were not evidently correlated
with any clinicopathological parameters.
Table I. Copy number alterations showing incidences of .20% in the examined UCs
Chromosomal loci Regions
a CN
b LI
c HI
d Chromosomal loci Regions
a CN
b LI
c HI
d
1p36.33–1p36.31 000554287–006656854 3 22.4 65.3 10q21.1–10q21.3 057989564–069900014 1 20.4 26.5
1p36.21–1p36.12 016167535–020948798 3 20.4 22.4 10q22.1–10q23.1 071904528–073262876 3 20.4 24.5
1p31.1 072550248–072568068 0 20.4 20.4 10q23.1 083089747–087102060 1 20.4 24.5
1q12–1q31.1 142721264–187457065 3 20.4 40.8 10q23.2–10q24.31 089445919–102120260 1 20.4 26.5
1q31.1–1q44 190299165–247190770 3 20.4 30.6 10q25.1–10q26.13 105709333–124981616 1 20.4 26.5
2q32.1–2q32.2 185846809–190742545 1 20.4 20.4 10q26.3 133783634–135066163 3 20.4 22.4
2q32.3–2q37.3 192350477–242717069 1 20.4 32.7 11p15.5–11p15.4 000182372–003270486 3 28.6 32.7
3p25.3 009517826–011146712 3 22.4 26.5 11q21–11q22.1 096386431–097377420 1 20.4 20.4
3p25.2–3p25.1 012038778–015468042 3 20.4 32.7 11q22.1–11q23.3 097429396–116543936 1 20.4 26.5
3p21.31 048346498–050680352 3 20.4 24.5 11q23.3–11q24.2 124714078–125280002 1 20.4 20.4
3p14.1 065390626–065748270 1 20.4 20.4 11q24.2 124714078–125280002 1 20.4 20.4
3p14.1–3p13 068561452–072819381 1 20.4 24.5 11q24.2–11q25 126760808–132830348 1 20.4 22.4
3p12.3 076229787–076504425 1 20.4 20.4 11q25 133367262–133662626 1 20.4 20.4
3p12.3 077466215–078924208 1 20.4 20.4 12p13.33 001767600–002412124 3 20.4 20.4
3p12.3 079019795–079019854 1 20.4 20.4 12p13.31 006172174–007239121 3 20.4 22.4
3p12.3–3p12.2 081674283–083271792 1 20.4 24.5 12q13.13–12q13.2 050511140–053289666 3 22.4 34.7
3q21.3 128095046–130849578 3 20.4 22.4 12q24.23–12q24.31 119012815–122594513 3 20.4 20.4
3q26.1 163997228–164101835 0 51.0 59.2 13q13.3 036216743–038434639 1 20.4 22.4
3q27.1–3q27.2 184336189–186044074 3 20.4 20.4 13q21.1 053204015–057297991 1 20.4 22.4
3q29 194947608–198141010 3 20.4 20.4 13q34 112711763–114123908 3 20.4 22.4
3q29 198287059–1993214468 3 20.4 20.4 14q11.1–14q11.2 018149473–019665348 1 20.4 40.8
4p16.3–4p16.2 000041413–004080171 3 22.4 30.6 14q12 025347676–028443093 1 20.4 20.4
4p16.2–4p16.1 004863024–009205888 3 20.4 30.6 14q12–14q32.31 028746840–101366386 1 20.4 36.7
4p16.1 009410429–009800836 3 20.4 20.4 14q32.33 103609874–105504791 3 20.4 30.6
4q13.2 069057735–069165872 0 38.8 67.3 15q11.1–15q11.2 018683110–020387386 1 24.5 36.7
4q28.3 135481517–138478960 1 22.4 26.5 15q11.2 018683110–019435559 3 20.4 20.4
4q34.1 172444145–173706467 1 20.4 20.4 15q21.3 054364049–055292702 1 20.4 20.4
4q34.2–4q35.1 176641828–183811059 1 20.4 24.5 15q24.1–15q24.2 072125930–073833248 3 20.4 20.4
4q35.1 184728685–184971082 1 20.4 20.4 16p13.3 000028087–003208434 3 22.4 36.7
4q35.1–4q35.2 186466884–190719413 1 20.4 24.5 16p13.2 007398132–007610763 1 20.4 20.4
5p15.33 000075149–004092634 3 20.4 46.9 16p11.2 028394123–031439837 3 20.4 32.7
5p15.32–5p15.2 005757937–010857368 3 20.4 22.4 16q21 057623929–059070656 1 20.4 20.4
5p15.2–5p15.1 014200030–016428467 3 20.4 20.4 16q22.1 065296755–066623461 3 20.4 22.4
5q11.1–5q35.3 049595677–180644869 1 22.4 63.3 16q24.1–16q24.3 083207007–088690615 3 20.4 26.5
6p21.33–6p21.32 031497746–032281493 3 20.4 24.5 17p13.3–17p11.2 000029169–020234630 1 20.4 32.7
6p21.32–6p21.31 033247001–034187994 3 20.4 20.4 17q11.2 023533773–024473421 3 20.4 20.4
6p21.2–6p21.1 040188750–044391792 3 20.4 24.5 17q21.2–17q21.31 037792629–038922402 3 20.4 20.4
6q16.3–6q21 101107740–105665855 1 20.4 22.4 17q21.31 039360337–041458716 3 20.4 20.4
6q21–6q22.2 113047208–117916793 1 20.4 20.4 17q21.32–17q21.33 043930335–046303881 3 20.4 24.5
7p22.2 000140213–003449208 3 20.4 42.9 17q24.3–17q25.3 067481954–078653589 3 20.4 49.0
7p22.2–7p22.1 003871971–005993219 3 20.4 28.6 18p11.32–18p11.23 000004316–008103527 1 20.4 22.4
7p13 043944978–045169498 3 20.4 24.4 18p11.21 013020518–013601674 1 20.4 20.4
7q11.23 072356188–075985576 3 22.4 22.4 18q11.2 019251951–019903282 1 20.4 20.4
7q22.1 099307676–102120122 3 20.4 30.6 18q12.1–18q23 023887204–076111023 1 20.4 36.7
8p23.2–8p23.1 002209252–006655643 1 20.4 22.4 19p13.3–19p13.11 000064418–019716580 3 28.6 53.1
8p23.1 007040596–008140129 1 24.5 32.7 19q12–19q13.42 032981858–061360576 3 20.4 42.9
8p22 013056908–018810539 1 20.4 22.4 20p13–20q13.33 000008747–062379118 3 26.5 57.1
8p21.3–8p21.2 023372368–027249779 1 20.4 24.5 21p11.2 009896630–013600286 1 20.4 34.7
8p21.1–8p12 027678573–037057454 1 20.4 28.6 21q22.3 041606431–046914745 3 20.4 38.8
8q11.1–8q24.3 047062121–146264902 3 20.4 61.2 22q11.21 016646613–019038934 3 22.4 44.9
9p24.3–9p11.2 000153131–044199460 1 20.4 53.1 22q11.21 018989547–018989606 0 20.4 20.4
9p11.2–9q34.3 045419207–140241935 1 20.4 51.0 22q11.21 019835358–020440240 3 20.4 24.5
9p21.3 021698371–022372349 0 20.4 26.5 22q11.23 021944430–022991816 3 20.4 22.4
9p12–9p11.2 041970428–046018111 3 26.5 36.7 22q12.3–22q13.1 034773534–038422701 3 20.4 40.8
9p24.3 000153131–140241935 1 20.4 53.1 22q13.3–22q13.33 049000786–049565875 3 20.4 20.4
9q34.2–9q34.2 135191259–139424835 3 20.4 22.4
aBased on NCBI36/hg18.
bCopy number (If a UC shows copy number heterogeneity, the copy number observed in the major area within the tumor is considered to be the copy number of theU C ) .
cLowest incidence of copy number alterations in the chromosomal regions (%).
dHighest incidence of copy number alterations in the chromosomal regions (%).
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data
Using two-dimensional unsupervised hierarchical clustering analysis
based on copy numbers and all array CGH probes, the 49 UCs were
clustered into three subclasses, clusters A, B1 and B2 (Figure 4), which
contained 4, 12 and 33 tumors, respectively. The average number of
probes on which loss (copy number 1 or 0) or gain ( 3) was detected
was signiﬁcantly higher in cluster A (99 499 ± 29 879) than in cluster
B1 (63 324 ± 40 064) and cluster B2 (46853 ± 35000, P 5 0.0271). As
shown in Table II, the average number of probes on which gain ( 3)
was detected was signiﬁcantly higher in cluster A than in clusters B1
and B2 (P 5 0.0153), whereas the difference in the average number of
probes onwhich loss(1or0) was detected amongclustersA,B1 and B2
did not reach statistical signiﬁcance. The average number of probes on
which a copy number of .3 was detected was signiﬁcantly higher in
cluster A than in clusters B1 and B2 (P 5 0.0053). These data indicated
Fig. 3. Correlations between copy number alterations on representative chromosomes and clinicopathological parameters of UCs. The 49 UCs (T1 to T49)
were divided into recurrence-negative (n 5 42) and -positive (n 5 7) cases (A, C and J), histologically low-grade (n 5 19) and high-grade (n 5 30) tumors (B, E,
F, H and O), lymph node metastasis (pN)-negative (n 5 44) and -positive (n 5 5) tumors (D), lymph vessel involvement (Ly)-negative (n 5 33) and -positive (n 5
16) tumors (G, L and M), and papillary (n 5 28) and non-papillary (n 5 21) tumors (I, K and N).  , negative; þ, positive. The incidence of copy number
alterations on chromosomes 1 (A), 2 (B and C), 3 (D), 4 (E), 5 (F), 6 (G), 7 (H), 8 (I), 10 (J), 15 (K), 17 (L), 19 (M and N) and 20 (O) in each of the UC groups is
shown. Gains (copy number:  3) and losses (copy number: 1 or 0) are indicated in the upper and lower halves, respectively. Copy numbers of 0, 1, 3 and more are
shown in dark red, light red, light blue and dark blue, respectively.
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466that copy number alterations, especially chromosomal gain, were
accumulated in cluster A in comparison with clusters B1 and B2.
Correlation between genetic clustering of UCs and DNA methylation
status revealed by BAMCA, MSP and COBRA
As shown in Table II, the average number of BAC clones showing
DNA hypomethylation was signiﬁcantly higher in cluster A than in
clusters B1 and B2 (P 5 0.0487), whereas there were no signiﬁcant
differences in the average number of BAC clones showing DNA hy-
permethylation among the three clusters. The incidence of DNA
methylation on CpG islands of the p16 and hMLH1 genes and the
MINT-1, MINT-2 and MINT-12 clones was 11 of 49 (detected/ana-
lyzed, 22.4%), 1 of 49 (2.0%), 9 of 49 (18.4%), 1 of 49 (2.0%) and 11
of 49 (22.4%), respectively. As shown in Table II, the average number
of methylated C-type CpG islands was signiﬁcantly higher in cluster
B1 than in clusters A and B2 (P 5 0.0412). Taken together, the data
suggested that copy number alterations associated with overall DNA
hypomethylation and regional DNA hypermethylation on C-type CpG
islands were accumulated in clusters A and B1, respectively, when
deﬁned on the basis of copy number alterations.
Discussion
We and other groups have demonstrated copy number alterations in
UCs for each chromosome or chromosome arm by Southern blotting,
PCR–LOH and CGH analyses (3,4,6,7,9–11,25). Several array CGH
analyses of UCs have also been performed using tiling BAC arrays
(15,16,18). However, such analyses were unable to deﬁne the break
points in detail. We here examined copy number alterations in UCs
using a high-resolution (244K) oligonucleotide array capable of de-
ﬁning break points more precisely.
Copy numbers not corresponding to whole numbers were detected
in the array CGH proﬁles of some UCs. In such cases, FISH analysis
revealed copy number heterogeneity even within a single UC (e.g.
cancer cells showing both two signalsand one signal canbe seen in T4
in Figure 1E). In UCs, heterogeneity of cellular atypia is frequently
observedin histological specimens: a small area showing highergrade
cellular atypia develops within a low-grade UC or cancer cells gain
higher grade cellular atypia before they start to disrupt the basal
membrane and invade into subepithelial tissues. It is feasible that copy
number heterogeneity corresponds to such histological heterogeneity
during the multistep malignant progression of UCs.
Our meticulous examination revealed the clinicopathological
impacts of copy number alterations at various chromosomal loci
(Figures 2 and 3 ). Losses (copy number 1 or 0) of 2q33.3–q37.3,
4p15.2–q13.1 and 5q13.3–q35.3 and gains (copy number  3) of
7p11.2–q11.23 and 20q13.12–q13.2 were signiﬁcantly correlated
with higher histological grade of UCs. Gain of 7p21.2–p21.12 was
signiﬁcantly correlated with deeper invasion. Losses of 6q14.1–q27
and 17p13.3–q11.1 and gains of 19q13.12–q13.2 and 20q13.12–
q13.33 were signiﬁcantly correlated with lymph vessel involvement.
Loss of 16p12.2–p12.1 and gain of 3q26.32–q29 were signiﬁcantly
correlated with vascular involvement. Losses of 5q14.1–q23.1,
6q14.1–q27, 8p22–p21.3, 11q13.5–q14.1 and 15q11.2–q22.2 and
gains of 7p11.2–q11.22 and 19q13.12–q13.2 were signiﬁcantly
correlated with tumor conﬁguration (development of a non-papillary
Fig. 4. Unsupervised two-dimensional hierarchical clustering analysis based
on array CGH analysis of UCs (T1 to T49). Forty-nine patients with UCs
were hierarchically clustered into three subclasses, clusters A (n 5 4), B1
(n 5 12) and B2 (n 5 33), based on copy numbers. Copy numbers of 0 or 1
(loss), 2 (no change) and  3 (gain) on each probe are shown in blue, yellow
and red,respectively. The clustertreesfor tumorsand probes are shown at the
top and to the left of the panel, respectively.
Table II. Correlation between genetic clustering of UCs and copy number alterations and DNA methylation status
Copy number and DNA methylation status Genetic clustering of UCs
Cluster A Cluster B1 Cluster B2
Average numbers of array CGH probes
showing copy number alterations
Loss (1 or 0) 24 525 ± 15404 40 826 ± 31644 26 448± 28 462
Gain ( 3) 74 974± 38013
 
22 498 ± 15484 20 405 ± 17 369
Gain (.3) 1897 ± 1001
y 236 ± 315 209 ± 361
Average numbers of BAC clones showing
DNA methylation alterations
DNA hypomethylation 312 ± 44
z 189 ± 95 236± 91
DNA hypermethylation 334± 85 254± 112 287± 77
Average numbers of C-type CpG
islands showing DNA methylation
0.75 ± 0.96 1.33 ± 0.98
§ 0.58 ± 0.79
 P 5 0.0153 to clusters B1 and B2.
yP 5 0.0053 to clusters B1 and B2.
zP 5 0.0487 to clusters B1 and B2.
§P 5 0.0412 to clusters A and B2.
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467tumor). Possibly affected genes, which are located at such chromo-
somal loci and for which correlations with growth, motility and
invasiveness of tumor cells and tumorigenesis have already been re-
ported, are listed in supplementary Table S2, available at Carcinogen-
esis Online. Signiﬁcant correlations between copy number alterations
on such loci and clinicopathological parameters reﬂecting the malig-
nant potential of UCs may be at least partly attributable to silencing or
activation of the listed genes. Moreover, such chromosomal loci are
important targets for exploration of unidentiﬁed tumor-related genes
that participate in the malignant progression of UCs; the products of
such genes may become target molecules for therapy of UCs. In
addition, losses of 1p32.2–p31.3, 10q11.23–q21.1 and 15q21.3 were
signiﬁcantly correlated with recurrence of UCs: copy numbers at such
chromosomal loci may become indicators for prognostication of pa-
tients with UCs (estimation of recurrence risk using surgically re-
sected specimens).
On the other hand, although the incidence of gain of the entire arm
of chromosome 8q and losses of the entire arm of chromosomes 9q,
11p and 14q were not signiﬁcantly correlated with any of the exam-
ined clinicopathological parameters reﬂecting the malignant potential
of UCs, the incidence of such copy number alterations was generally
high. Such copy number alterations may occur in the earlier stage of
development of both papillary and non-papillary UCs. Therefore,
gatekeeper genes for urothelial carcinogenesis may exist on 8q, 9q,
11p and 14q. Combinations of the copy numbers of 8q, 9q, 11p and
14q could become applicable as indicators for the early diagnosis of
UCs based on examination of urinary sediments and tissue specimens.
Moreover, the incidence of homozygous deletion on only 11 con-
tinuous oligonucleotide probes on 4q13.2 was high (67.3%) and the
UGT2B17 gene is located within this homozygously deleted lesion.
Copy number polymorphism of the UGT2B17 gene is reportedly
associated with smoking-related cancer development (37), and a sig-
niﬁcant association between UCs and smoking has been demonstrated
epidemiologically (38). Since there are many family genes, the
exact copy numbers of the UGT2B17 gene were evaluated by quan-
titative PCR using speciﬁc primer sets (supplementary Table S3 is
available at Carcinogenesis Online). Levels of expression of messen-
ger RNA (mRNA) for the UGT2B17 gene normalized relative to the
expression of glyceraldehyde-3-phosphate dehydrogenase mRNA
were also examined by quantitative reverse transcription (RT)–PCR
analysis (supplementary Table S3 is available at Carcinogenesis
Online) in 37 of the 49 UCs for which RNA samples were available.
Quantitative RT–PCR data for the UGT2B17 gene in 28 UCs
showing homozygous deletion (copy number 0) was 3.53 ± 6.40,
being signiﬁcantly lower than that in 9 UCs not showing it (61.61 ±
98.32, P 5 0.008176). Since the homozygous deletion actually re-
sulted in gene silencing, the correlation between the copy number of
the UGT2B17 gene and susceptibility to UCs should be further
examined.
UCs were grouped into three subclasses, clusters A, B1 and B2,
based on copy number alterations. In cluster A, copy number altera-
tions, especially chromosomal gains, revealed by array CGH analysis,
and DNA hypomethylation revealed by BAMCA were both accumu-
lated in a genome-wide manner. DNA hypomethylation may result in
chromosomal instability through changes in chromatin conﬁguration
and enhancement of chromosomal recombination (39). Although such
correlation between DNA hypomethylation and chromosomal instabil-
ity has been observed in experimental models (40) and human immu-
nodeﬁciency, centromeric instability and facial anomalies syndrome
(41) and cancers (25,42), details of the DNA methylation status around
each of the chromosome breakpoints are still unclear. UCs in cluster A
may beidealforexaminationofDNAmethylationstatusaroundbreak-
points to further clarify the molecular mechanisms responsible for
chromosomal instability resulting from DNA methylation alterations.
Cluster B1 showed accumulation of regional DNA hypermethylation
on C-type CpG islands. In addition, chromosomal losses tended to be
accumulated in cluster B1 in comparison with clusters A and B2,a l -
though such differences did not reach statistical signiﬁcance. The can-
cer phenotype associated with accumulation of DNA methylation on
C-typeCpG islands isdeﬁnedasthe CpG islandmethylatorphenotype,
and such accumulation is generally associated with frequent silencing
of tumor-related genes due to DNA hypermethylation only and/or
a two-hit mechanism involving DNA hypermethylation and LOH in
human cancers of various organs (22). Silencing of tumor-related
genes due to DNA hypermethylation and chromosomal losses may
be critical for the development of UCs belonging to cluster B1.I n
cluster B2, the number of BAC clones showing both DNA hypo- and
hypermethylation by BAMCA was rather high, and the number of
probes showing loss or gain by array CGH was rather low, in compar-
ison with cluster B1, although such differences did not reach statistical
signiﬁcance. In addition to copy number alterations, genome-wide
DNA methylation alterations may also participate in the development
of UCs belonging to cluster B2.
The number of CpG sites in CpG islands and repetitive sequences
in 5# regions, introns, exons and non-coding regions on BAC clones
showing DNA hypomethylation in UCs are summarized in supple-
mentary Table S4, available at Carcinogenesis. DNA hypomethyla-
tion was observed in BAC clones including both CpG islands and
repetitive sequences, possibly resulting in activation of tumor-related
genes and/or parasitic elements and loss of chromosomal integrity.
Silencing of representative genes on affected chromosomal loci
was conﬁrmed using quantitative RT–PCR analysis (supplementary
Table S3 is available at Carcinogenesis Online). Although DNA
methylation of the p16 gene was detected using MSP, quantitative
examination using pyrosequencing (supplementary Table S3 is avail-
able at Carcinogenesis Online) revealed generally low DNA methyl-
ation levels (1.82 ± 0.65%) in all UCs. Therefore, correlations
between copy numbers based on array CGH analysis and mRNA
expression levels based on quantitative RT–PCR analysis were exam-
ined. The p16 gene was silenced in 11 UCs showing homozygous de-
letion (copy number, 0; quantitative RT–PCR data, 1.24 ± 1.20),
whereas the mRNA expression level in 27 UCs not showing it was
104.1 ± 205.11 (P 5 0.00000357). On the other hand, the DNA meth-
ylation level of the CXCL12 gene was 12.59 ± 18.43% for the UCs as
a whole. The CXCL12 gene was silenced in 2 UCs with DNA meth-
ylationlevelsof 50%(mRNAexpressionlevel:1.81±1.00)butnotin
34 UCs with DNA methylation levels of ,50% (mRNA expression
level: 24.45 ± 34.04). The level of expression of mRNA for the ERBB4
gene in 18 UCs showing a DNA methylation level of  5% and/or
chromosomal loss (copy number 0 or 1) was 59.1 ± 101.2 and tended to
belowerthanthatin20UCswithaDNAmethylationlevelof,5%and
a copy number of 2 (128.4 ± 259.3), suggesting the possibility of in-
activation due to a combination of DNA hypermethylation and
chromosomal loss, although such differences did not reach statistically
signiﬁcant levels. Taken together, the data suggest that genetic
and epigenetic alterations (copy number alterations and DNA methyl-
ation alterations) are not mutually exclusive during urothelial carcino-
genesis. Reﬂecting the clinicopathological diversity and histological
heterogeneity of UCs, genetic and epigenetic events appear to accumu-
late in a complex manner during the developmental stage of individual
tumors.
Supplementary material
Supplementary Tables S1–S4 can be found at http://carcin.
oxfordjournals.org/
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